News

The Phase 1 study will assess the safety and pharmacokinetic profiles of two different formulations of Fanapt in patients with schizophrenia. Under an agreement signed in 2009 with

Sativex is a cannabinoid medicine for the treatment of spasticity due to multiple sclerosis which is also in development in cancer pain and neuropathic pain of various origins.

Under the agreement, Heptares is expected to work on its proprietary StaR (stabilized receptor) technology to engineer its thermally stabilized forms of the GPCR as the basis for

The trial was designed to investigate the safety of three different doses of NP2 Enkephalin and also to investigate efficacy measurements of pain relief in subjects suffering from

MorphoSys will receive committed annual license fees, success-based development milestones, in addition to royalties on sales of marketed drug products emerging from the collaboration. MorphoSys chief scientific officer

IMA901 is a therapeutic cancer vaccine comprising 10 tumor-associated peptides (TUMAPs) that are frequently found to be over-expressed in the majority of patients suffering from renal cell carcinoma.

The new patent, entitled ‘Proteome-wide quantification of small molecule binding to cellular target proteins,’ (EP2045332B1) supports company’s chemical proteomics solutions for research and development. Cellular Target Profiling enables

The decision has been taken by DMC following a pre-specified interim analysis from the Phase II and III clinical trial. The partners said the trial did not meet

MycoTOOL test is a NAT-based detection system that is used for mycoplasma biosafety testing of approved biological products. Release testing with the MycoTOOL PCR-test from Roche Custom Biotech,